臺灣博碩士論文加值系統

背景
本實驗係採回溯性分析南部某醫學中心進行肝臟移植之兒童病患，共收集30位病患，分成兩組比較cyclosporine的監測方式：一組是以服用cyclosporine後2小時的濃度(C2 n = 15)，另一組是以服藥前的波谷濃度(C0 n = 15)來調整劑量。
實驗方法
Cyclosporine (Neoral®) 的初始劑量是以300 mg/m2/dose，而劑量的調整是以其要求達到的預期值 (target level) 為主。兩種方式的評估內容主要評估術後3個月內急性排斥的發生、肝臟功能、腎臟功能、cyclosporine的使用劑量、不良反應、感染率。
實驗結果
兩組病患的基本資料大致相似，除了在C2組有3位病童在手術時的年紀是滿10歲，其餘病患皆與C0組相仿。整體的急性排斥的發生率C2組 ( 2/15 ; 13.3 % ) 與C0組 ( 3/15 ; 20 % ) 在統計上並無明顯差異 (P > 0.05) 。C2組的病人於術後3天即達到預期值者，沒有一位病人發生急性排斥；相反的，C0組達到預期值的天數與急性排斥之間無法有相關性。肝臟功能、腎臟功能、不良反應、感染率兩組皆無明顯差異 (P > 0.05) ，除了在C2組第12週alanine transaminase (ALT) 值是明顯比C0組高，因為在C2組有較多的病人發生肝臟動脈、肝臟靜脈栓塞、膽管炎 (7位在C2組； 4位在C0組) 而且C2組急性排斥的發生時間都在術後第2至3個月而C0組多發生在第1個月。Cyclosporine的使用劑量兩組在術後第1週及4週有明顯差異 (P < 0.05) 。術後第1週C2組劑量是39.55 mg/kg/day明顯多出C0組的 29.39 mg/kg/day (P < 0.05) 。但是當術後4週結果卻相反，C0組的 17.38 mg/kg/day明顯多出C2組劑量12.9 mg/kg/day (P < 0.05) 。
結論
使用C2或C0的監測方式在整體的急性排斥率及發炎的嚴重度在統計無差異。雖然初期C2組cyclosporine的使用劑量比較高，然而在其他安全性評估卻未見有差異，因此使用如此劑量應是安全。

英文摘要( Abstract )
Keywords: pediatric liver transplantation, cyclosporine, acute rejection
Background. A retrospective study was conducted at a medical hospital in the southern Taiwan, involving 30 de novo pediatric liver transplant patients to compare the clinical usefulness of monitoring 2-hr post-dose cyclosporine levels (C2) (n = 15) with conventional trough cyclosporine blood levels (trough, pre-dose) (C0) (n = 15).
Methods. Neoral oral therapy was initiated at 300 mg/m2/dose and dose adjusted according to predetermined C2 or C0 target level ranges. The efficacy evaluation variable was based on a composite endpoint of biopsy-proven rejection, renal function, liver function, dosage, adverse effects, infection, during the first 3 months after operation from the study.
Results. Baseline characteristics were similar, except the mean age at operation. Overall incidence of acute rejection was not significantly different between the two groups (P > 0.05) . For biopsy-proven acute rejections, the incidence of moderate histological diagnosis was lower in the C2 group than in the C0 group. C2 patients who reached minimum target cyclosporine levels by day 3, the rejection rate was zero for the first 3 months, whereas there was no difference in the incidence of rejection in C0 patients, irrespective of time to reach target levels. The renal function, liver function (except in the 12 week data because C2 group the incidences of hepatic artery, venous thrombosis, cholangitis were large than C0 group) (7 in C2 and 4 in C0) and adverse effects were no difference between the two groups. The dose of cyclosporine was significantly different in the both groups on the day 7 (P < 0.05) and day 30 (P < 0.05) . On the day 7, the mean dose of C2 group (39.55 mg/ kg/day) was significantly higher than that in the C0 group (29.39 mg/kg/day) . In the contrast, on the day 30 the average dose of C2 group (12.9 mg/kg/day) was significantly lower in the C0 group (17.38 mg/kg/day).
Conclusion. There was no significant different between C2 and C0 about the overall incidence of acute rejection and the histological severity of acute rejection. Although the dose was higher in C2 group within first week after operation, there was no difference about renal function and safety profile between the 2 groups.

圖次目錄------------------------------------------------------------------------表次目錄------------------------------------------------------------------------中文摘要------------------------------------------------------------------------英文摘要------------------------------------------------------------------------本文 壹、 緒論一、 器官移植的發展------------------------------------------- 二、 研究背景---------------------------------------------------- 三、 用於孩童監測cyclosporine濃度的方法比較-------- 四、 實驗目的---------------------------------------------------五、 移植後細胞免疫的機轉---------------------------------六、 免疫抑制劑的機轉---------------------------------------七、 Cyclosporine之基本性質與發展----------------------八、 Neoral ® 藥物動力學------------------------------------九、 Cyclosporine的藥物交互作用-------------------------十、 Cyclosporine的副作用----------------------------------十一、劑量及用法------------------------------------------------貳、 病人及實驗方法一、 實驗病人的篩選-------------------------------------------二、 實驗方法及用藥-------------------------------------------三、 急性排斥的判斷-------------------------------------------四、 分析統計方式----------------------------------------------五、 Cyclosporine濃度監測方式------------------------------六、 Cyclosporine濃度監測的抽血時間--------------------- 參、 結果與討論一、 病人的基本資料-------------------------------------------二、 兩組病人術後生化值的比較----------------------------三、 兩組病人使用cyclosporine劑量的比較--------------四、 急性排斥率-------------------------------------------------五、 安全性評估-------------------------------------------------六、 分析統計之結果-------------------------------------------肆、 結論--------------------------------------------------------------------伍、 參考文獻--------------------------------------------------------------陸、 附錄-------------------------------------------------------------------- IIIIVVI138910122023252629323335353636373741475253575862

伍﹑參考文獻
Akhlaghi, F., Andrew, K. 2002. Distribution of cyclosporine in organ transplant recipients. CLIN PHARMACOKINET. 41(9) : 615-637.
Anaizi, N. 2001. Drug interactions involving immunosuppressive agents. GRAFT. 4 : 232-47.
Angelo, M., Mattos, D., Olyaei, A.J., William, M. 2000. Nephrotoxicity of immunosuppressive drugs : long-term consequences and challenges for the future. AM J KIDNEY DIS. 35(2) : 333-346.
Antiga, D., Dhawan, L.A., Portmann, B., Francavilla, R., Rela, M., Heaton, N., Mieli-Vergani, G. 2002. Late cellular rejection in paediatric liver transplantation : aetiology and outcome. TRANSPLANTATION. 73(1) : 80-4.
Bantle, J.P., Paller, M.S., Boudreau, R.J. 1990. Long—term effects of cyclosporine on renal function in organ transplant recipients. J LAB CLIN MED. 115 : 233-240.
Barkmann, A., Bjorn, N., Hartmut, H.J., Klaus, H.W., Emmanouilidis, N., Rosenau, J., Matthias, J., Matthias, W., Michael P., Hans J. 2000. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. TRANSPLANTATION . 69(9) : 1886-1890.
Belitsky, P., Levy, G.A., Johnston, A. 2000. Neoral absorption profiling : an evolution in effectiveness. TRANSPLANTATION PROCEEDING. 32(3) : 45S-52S.
Belitsky, P., Dunn, S., Atholl, J., Levy, G.A. 2000. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients. CLIN PHARMACOKINET. 39(2) : 117-125.
Canadian Neoral renal transplantation study group. 2001. Absorption profiling of cyclosporine microemulsion (Neoral®) during the first 2 weeks after renal transplantation. TRANSPLANTATION . 72(6) : 1024-32.
Chardot, C., Nicoluzzi, J.E., Janssen, M., Sokal, E., Lerut, J., Otte J.B., Reding, R. 2001. Use of Mycophenolate mofetil as rescue therapy after pediatric liver transplantation. TRANSPLANTATION. 71(2) : 224-229.
Coorney, G.F., Habucky, K., Hoppu, K. 1997. Cyclosporine pharmacokinetics in paediatric transplant recipients. CLIN PHARMACOKINET. 32 : 481-95.
Flye, M.W. 1995. Immunosuppression therapy. In “Atlas of organ transplantation”. 1st ed. pp. 25-46. W.B. Saunders Company. United States of America.
Friman, S., Bäckman, L. 1996. A new microemulsion formulation of cyclosporine. CLIN PHARMACOKINET. 30(3) : 181-193.
Gomez, M.N., Herrero, J.I., Quiroga, J., Sangro, B., Pardo, F., Cienfuegos, J.A., Prieto, J. 2001. Prognostic model for early acute rejection after liver transplantation. LIVER TRANSPLANT. 7(3) : 246-54.
Grant, D., Kneteman, N., Tchervenkov, J. 1999. Peak cyclosporine levels (Cmax) correlated with freedom from liver graft rejection: results of a prospective, randomized comparison of Neoral® and Sandimmun® for liver transplantation (NOF-8). TRANSPLANTATION. 67 : 1133-7.
Gupta, P., Hart J., Cronin, D., Kelly, S., Michael, J. and Brady, L. 2001. Risk factors for chronic rejection after pediatric liver transplantation. TRANSPLANTATION. 72 : 1098-1102.
Halloran, P.F., Helms, L.M., Kung, L. 1999. The temporal profile of calcineurin inhibition by cyclosporine in vivo. TRANSPLANTATION. 68 : 1356-61.
Kilic, M., Kahan, B.D. 2000. New trends in immunosuppression. DRUGS TODAY. 36(6) : 395-410.
Kuby, J. 1997. Overview of the immune system. In “Immunology”. pp. 1-18. W.H. Freeman and company. New York.
Kuby, J. 1997. Transplantation immunology. In “Immunology”. pp. 561-580. W.H. Freeman and company. New York.
Lemire, J., Capparell, E.V., Benador, N. 2001. Neoral pharmacokinetics in Latino and Caucasian pediatric renal transplant recipients. PEDIATR NEPHROL. 6(4) : 311-4.
Levy, G.A., Burra, A., Cavallari, A., Duvoux, C., Lake, J.R., Mayer, A.D., Mies S., Pollard, S.G., Varo, E., Villamil, F., Johnston, A. 2002. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-HR post-dose level (C2). TRANSPLANTATION. 73(6) : 953-959.
Levy, G.A., Lake, J.R., Beauregard-Zollinger, L. 2000. Improved clinical outcomes for liver transplant recipients using cyclosporine blood level monitoring based on two-hour post-dose levels. TRANSPLANTATION. 69-S 387.
Levy, G.A. 2001. C2 monitoring strategy for optimising cyclosporine immunosuppression from the Neoral formulation. BIODRUGS. 15(5) : 279-290.
Levy, G.A. 2001. Neoral C2 in liver transplant recipients. TRANSPLANTATION PROCEEDINGS. 33 : 3081-3091.
Levy, G.A. 2001. Long—term immunosuppression and drug interactions. LIVER TRANSPLANT. 7(11) : 53-59.
Mar, M.D., Gatta F.D., Dolores, S.B., Alfonso, D.G. 2002. Immunosuppressive therapy for pediatric transplant patients. Pharmacokinetic considerations. CLIN PHARMACOKINET. 41(2) : 115-135.
Morris, R.G., Russ, G.R., Cervel, M.J. 2002. Comparison of trough, 2 hour, and limited AUC blood sampling for monitoring cyclosporine (Neoral®) at day 7 post-renal transplantation and incidence of rejection in the first month. THER DRUG MONIT. 24(4) : 479-86.
Mueller, E.A., Kovarik, J.M., Bree, J.B. 1994. Improved dose linearity of cyclosporine pharmacokinetics from microemulsion formulation. PHARM RES. 11: 301-4.
Oellerich, M., Armstrong, V.W. 2002. Two-hour cyclosporine concentration determination: an appropriate tool to monitor Neoral therapy ? THER DRUG MONIT. 24(1) : 40-46.
Schroeder, T.J., Hariharan, S., First, M.R. 1995. Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations. TRANSPLANTATION PROCEEDINGS. 27 : 837-9.
Trull, A.K., Tan, K.C. 1995. Absorption of cyclosporine conventional and new microemlsion formulations, in liver transplant recipients with external biliary diversion. CLIN PHARMACOL. 39 : 627-31.
Yang, W.C., Chen, Y.F., King, K.L., Wu,T.H., Tang, J.J. 2000. Optimization of cyclosporine therapy with abbreviated area under the curve method in renal transplant. TRANSPLANTATION PROCEEDINGS. 32 : 1685-1687.
Yee, G.C. 1991. Recently advances in cyclosporine pharmacokinetics. PHARMACOTHERAPY. 11(5) : 130S-4S.
陳瑞瑩‧黃莉蓉. 中華民國九十年十二月三十一日. 心臟移植免疫抑制劑之使用.藥學雜誌. 17(4) : 75-84.